Featured Publications
Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Barmada A, Klein J, Ramaswamy A, Brodsky N, Jaycox J, Sheikha H, Jones K, Habet V, Campbell M, Sumida T, Kontorovich A, Bogunovic D, Oliveira C, Steele J, Hall E, Pena-Hernandez M, Monteiro V, Lucas C, Ring A, Omer S, Iwasaki A, Yildirim I, Lucas C. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Science Immunology 2023, 8: eadh3455-eadh3455. PMID: 37146127, PMCID: PMC10468758, DOI: 10.1126/sciimmunol.adh3455.Peer-Reviewed Original ResearchConceptsMRNA vaccinesSARS-CoV-2 mRNA vaccinesSARS-CoV-2 mRNA vaccinationC-reactive protein levelsB-type natriuretic peptidePeripheral blood mononuclear cellsCardiac tissue inflammationDeep immune profilingSerum soluble CD163Vaccine-associated myocarditisCohort of patientsBlood mononuclear cellsCytotoxic T cellsLate gadolinium enhancementHypersensitivity myocarditisElevated troponinMRNA vaccinationImaging abnormalitiesNK cellsImmune profilingKiller cellsMyeloid responseNatriuretic peptideHumoral mechanismsInflammatory cytokinesSARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effectsEvidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriodRelationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study
Patel KM, Shafiq M, Malik AA, Cobanoglu A, Klotz M, Eric Humphries J, Lee A, Murray T, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Rojas R, Kuperwajs Cohen A, Omer SB, Gilliam WS. Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study. Vaccine 2022, 40: 4098-4104. PMID: 35660329, PMCID: PMC9135692, DOI: 10.1016/j.vaccine.2022.05.064.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationProspective cohort studyCare providersNonpharmaceutical interventionsChild care providersCohort studyLikelihood of vaccinationPreventative health behaviorsVaccinationHealth behaviorsCare programMandatory vaccinationSignificant associationVaccine mandatesDistrict of ColumbiaLarge healthInterventionPandemic controlCOVID-19Child care programsProvidersEmail surveyNonadherenceMeasuresAssessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study
Nisar M, Ansari N, Malik A, Shahid S, Lalani K, Chandna M, Younus A, Hasan Z, Khan U, Khalid F, Mahesar M, Farrukh Qazi M, Yildirim I, Jehan F, Omer S. Assessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study. Journal Of Infection 2023, 86: e144-e147. PMID: 36708775, PMCID: PMC9876011, DOI: 10.1016/j.jinf.2023.01.016.Peer-Reviewed Original ResearchCOVID-19 Vaccine Acceptance and Hesitancy Among Health Care Workers in Lebanon
Youssef N, Tfaily N, Moumneh M, Boutros C, Elharake J, Malik A, McFadden S, Galal B, Yildirim I, Khoshnood K, Omer S, Memish Z, Dbaibo G. COVID-19 Vaccine Acceptance and Hesitancy Among Health Care Workers in Lebanon. Journal Of Epidemiology And Global Health 2023, 13: 55-66. PMID: 36735184, PMCID: PMC9896451, DOI: 10.1007/s44197-023-00086-4.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesCross-Sectional StudiesHealth PersonnelHumansLebanonMalePandemicsSARS-CoV-2VaccinationConceptsHealth care workersCOVID-19 vaccine acceptanceVaccine acceptancePrevious infectionCare workersPrevious SARS-CoV-2 infectionSARS-CoV-2 infectionMethodsA cross-sectional studyCOVID-19 vaccination ratesCOVID-19 vaccinationCross-sectional studyCOVID-19 vaccineHealth care authoritiesVaccine uptakeVaccination ratesOrder of PhysiciansVaccine hesitancyGeneral populationHealthcare providersVaccineCare authoritiesInfectionCOVID-19 informationTrusted sourceCOVID-19 pandemic
2022
The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants
Kim D, Keskinocak P, Pekgün P, Yildirim İ. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. Scientific Reports 2022, 12: 7493. PMID: 35523832, PMCID: PMC9075929, DOI: 10.1038/s41598-022-11060-8.Peer-Reviewed Original ResearchConceptsOverall public health impactInfection attack rateCOVID-19 vaccineSARS-CoV-2Public health impactVaccine effectivenessAdverse outcomesMultiple vaccinesInitial efficacySuccessful immunization strategyImmunization strategiesVaccineLow-income countriesAttack rateEfficacyCOVID-19COVID-19 pandemicHealth impactsInfection spreadRecovered-deceased [SI(Q/F)RD] modelEfficacy levelsPandemicHospitalizationVaccinationVariantsNeutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine
2021
COVID-19 Vaccine Uptake Among US Child Care Providers
Patel KM, Malik AA, Lee A, Klotz M, Humphries JE, Murray T, Wilkinson D, Shafiq M, Yildirim I, Elharake JA, Diaz R, Reyes C, Omer SB, Gilliam WS. COVID-19 Vaccine Uptake Among US Child Care Providers. Pediatrics 2021, 148: e2021053813. PMID: 34452977, PMCID: PMC9277775, DOI: 10.1542/peds.2021-053813.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine uptakeVaccine uptakeCare providersChild care providersVaccination ratesSevere acute respiratory syndrome coronavirus 2Adult populationState public health leadersUS general adult populationAcute respiratory syndrome coronavirus 2General US adult populationRespiratory syndrome coronavirus 2Home-based child care programsSyndrome coronavirus 2US adult populationGeneral adult populationCross-sectional surveyPublic health implicationsPublic health leadersAnnual household incomeCoronavirus 2Care settingsInclusion criteriaCare programChild care settingsResource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach
Kim D, Pekgün P, Yildirim İ, Keskinocak P. Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach. Vaccine 2021, 39: 6876-6882. PMID: 34688498, PMCID: PMC8520874, DOI: 10.1016/j.vaccine.2021.10.025.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesHumansPandemicsResource AllocationSARS-CoV-2VaccinationVaccinesConceptsInfection attack rateVaccine typesDifferent vaccine typesResource-limited countriesHigh-efficacy vaccinesDifferent study parametersVaccine shortageEfficacy vaccineHealth outcomesLife-saving vaccinesVaccineVaccine distributionLow efficacyAttack rateStudy parametersEfficacyHigh efficacyCOVID-19COVID-19 pandemicDeceased (SIRD) modelDifferent resource allocation decisionsLimited accessCOVID-19 Vaccine Acceptance among Health Care Workers in the Kingdom of Saudi Arabia
Elharake JA, Galal B, Alqahtani SA, Kattan RF, Barry MA, Temsah MH, Malik AA, McFadden SM, Yildirim I, Khoshnood K, Omer SB, Memish ZA. COVID-19 Vaccine Acceptance among Health Care Workers in the Kingdom of Saudi Arabia. International Journal Of Infectious Diseases 2021, 109: 286-293. PMID: 34242765, PMCID: PMC8260488, DOI: 10.1016/j.ijid.2021.07.004.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesCross-Sectional StudiesHealth PersonnelHumansMaleSARS-CoV-2Saudi ArabiaVaccinesConceptsHealth care workersCOVID-19 vaccineCOVID-19 vaccine acceptanceVaccine acceptanceCare workersPublic health messaging campaignsCOVID-19 vaccine concernsPotential side effectsHealth care authoritiesVaccine concernsGeneral populationSide effectsVaccineCare authoritiesSaudi ArabiaHealth officialsMessaging campaignsDemographic characteristicsCOVID-19 informationKSA MinistryDemographic differencesParticipantsSignificance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation
Fujimoto AB, Keskinocak P, Yildirim I. Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation. Vaccine 2021, 39: 5055-5063. PMID: 34274126, PMCID: PMC8233959, DOI: 10.1016/j.vaccine.2021.06.067.Peer-Reviewed Original ResearchConceptsInfection attack rateAntibody testingSARS-CoV-2-specific antibodiesSpecific antibody testingAttack rateCOVID-19 vaccineSingle-dose vaccineCOVID-19 vaccine allocationDose vaccineSerology testingLimited vaccinesEligible individualsVaccine deploymentVaccination planVaccine supplySusceptible individualsNumber of casesRecovered (SIR) compartmental modelPeak dayUse of antibodiesVaccine allocationVaccinePeak infectionVaccinationSpecific antibodiesDelayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onsetFast Development of High-Quality Vaccines in a Pandemic
Pischel L, Yildirim I, Omer SB. Fast Development of High-Quality Vaccines in a Pandemic. CHEST Journal 2021, 160: e1-e3. PMID: 33848535, PMCID: PMC8102080, DOI: 10.1016/j.chest.2021.03.063.Commentaries, Editorials and Letters
2020
The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
McAteer J, Yildirim I, Chahroudi A. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. Clinical Infectious Diseases 2020, 71: 703-705. PMID: 32282038, PMCID: PMC7184475, DOI: 10.1093/cid/ciaa433.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Vaccines actCoronavirus 2Clinical trialsVaccine hesitancyVaccine candidatesNovel vaccinesCOVID-19COVID-19 pandemicVaccineTimes of COVID19PandemicTrials